Announcements Trials
Browse Landscape

Phase

Phase EARLY_PHASE1 1Phase 2 1

Status

Active not recruiting 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Plasma cell 2

Conditions

Smoldering Multiple Myeloma 2Triple Negative Breast Neoplasms 1Pancreatic Neoplasms 1PTEN-Altered Advanced Solid Tumors and HER2 Negative Breast Cancer 1Multiple Myeloma 1Breast Neoplasms 1Breast Diseases 1Acute Graft Versus Host Disease 1

Interventions

Lenalidomide 7Dexamethasone 5daratumumab 4Calcium Dobesilate 4dexamethasone acetate 3dexamethasone 21-phosphate 3auricularum 3Curcumin 3isatuximab 2iberdomide 2Leflunomide 2pomalidomide 1poly ICLC 1piperine 1pembrolizumab 1ixazomib 1fludarabine phosphate 1fludarabine 1citarinostat 1Watchful Waiting 1Urination 1Stem Cell Transplantation 1Resistance Training 1Propranolol 1Probiotics 1Peripheral Blood Stem Cell Transplantation 1PVX-410 vaccine 1Observation 1Metformin 1Melphalan 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Smoldering Multiple Myeloma × Leflunomide × 1 year × Clear all
NCT05014646 2026-04-30

Leflunomide for the Treatment of High-Risk Smoldering Multiple Myeloma in African-American and European-American Patients

City of Hope Medical Center

Phase 2 Active not recruiting
27 enrolled
Plasma cell

Smoldering Multiple Myeloma

NCT04370483 2026-01-05

Leflunomide for the Treatment of High-Risk Smoldering Multiple Myeloma

City of Hope Medical Center

Phase EARLY_PHASE1 Active not recruiting
1 enrolled
Plasma cell

Smoldering Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡